Non-alcoholic steatohepatitis (NASH) and fatty liver disease, now termed metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), represent significant therapeutic targets where GLP-1 RAs demonstrate substantial therapeutic potential, as evidenced by multiple clinical trials (Table 8) [98,99]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.